Rohto Pharmaceutical Publishes Transcript of Fiscal 2027 First-Half Results Briefing

• Rohto Pharmaceutical's November 13, 2026, interim earnings briefing featured President Hidetoshi Segi and Deputy President and CFO Masaya Saito.
• Management maintained March 2027 fiscal-year forecasts of JPY 372.3 billion revenue and JPY 45 billion operating profit, despite weaker Americas performance.
• The Americas operating profit forecast fell JPY 900 million to JPY 300 million, reflecting reduced US eye-drop shipments and higher costs.
• Japan's operating profit outlook rose JPY 500 million to JPY 23.9 billion, incorporating December eye-drop shipment price increases of roughly 5%-10%.
• Segi expected a limited earnings impact from the November 11 voluntary distribution-level recall of certain Vietnam-made eye-drop batches sold in Japan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rohto Pharmaceutical Co. Ltd. published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.